CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), today announced that the Company’s Chief Science Officer, Edward Wirth III, MD, PhD will be presenting at the Interdependence 2012 show currently being held in Vancouver through May 17th, 2012.
Dr. Wirth will participate in a panel discussion titled “Commercialization of SCI Research: Perspectives from the Private Sector.” The panel will be conducted today, Wednesday, May 16th from 2:45 to 4:00 pm. Dr. Wirth’s discussion, “Clinical Translation of Absorbable Biopolymers and Hydrogels for Acute Spinal Cord Injury,” will explore the challenges that InVivo Therapeutics has tackled in the course of bringing the novel biopolymer technology from the academic discovery stage to human clinical trials. InVivo has conducted multiple preclinical efficacy and safety studies in order to meet the rigorous scientific, ethical, and regulatory standards that are required to begin clinical trials of a therapeutic intervention that requires administration directly into the acutely injured spinal cord.
Dr. Wirth will also present a poster on data from the Company’s pilot primate study on Thursday, May 17th from 9:45 to 10:15 am.
InVivo Chief Executive Officer Frank Reynolds noted, “Ed is an ideal panel participant as he possesses deep experience guiding SCI technologies from the lab through the FDA, with detailed knowledge of the latest advances in biopolymer and hydrogel treatments. Interdependence 2012 is an important event for the SCI industry that presents innovations in a number of practice areas.”
Dr. Wirth joined InVivo after serving for seven years as Medical Director, Regenerative Medicine at Geron Corporation, where he led the first human studies using Geron’s application of human progenitor cells to spinal cord injury. Dr. Wirth received a Ph.D. in neuroscience and an M.D. from the University of Florida, and earned a B.A. in physics from Rollins College in Winter Park, Fla.
The Interdependence 2012 program features the latest findings from peer-reviewed researchers and clinicians in a comprehensive range of SCI-related subjects. Research teams and organizations from Denmark, Switzerland, Australia, China, UK, Belgium, USA and Canada will share their work and present the newest treatments and technologies in the field. The conference is produced by the Rick Hansen Foundation, a registered charitable organization that provides leadership to create more accessible and inclusive communities and find a cure for spinal cord injury (SCI). For more information, visit www.rickhansen.com/What-We-Do/Interdependence-2012.aspx.
For more information about InVivo Therapeutics’ technologies, visit www.invivotherapeutics.com.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.